Daniel Spitz, MD Co-Authors Research Study on PI3K Inhibitor Buparlisib

Fort Myers, Fla., Nov. 21, 2019 — Medical Oncologist Daniel Spitz, MD, who practices at the Florida Cancer Specialists (FCS) location in West Palm Beach, was a co-author of a new study evaluating the efficacy of buparlisib, an oral inhibitor drug of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases, which is one of the most promising new classes of potential drug targets.

Daniel-Spitz-MDAccording to an article published by PubMed Centralâ in the U.S. National Institutes of Health’s National Library of Medicine, “The phosphoinositide 3-kinase (PI3K) pathway, a critical signal transduction system linking oncogenes and multiple receptor classes to many essential cellular functions, is perhaps the most commonly activated signaling pathway in human cancer.” Because it is so common, there is a lot of research focused on developing cancer therapies that interrupt or block this pathway, thus inhibiting tumor growth.

In this Phase 2 study, patients with either solid or hematologic malignancies with PI3K pathway activation and progression on or after standard treatment received buparlisib (100 mg once daily). There were 146 patients enrolled in the study, with colorectal, sarcoma and ovarian tumor types. The goal of the study was to determine whether treatment with buparlisib monotherapy demonstrated sufficient efficacy in PI3K pathway-activated tumors to warrant further study. To evaluate, the researchers assessed clinical benefit response or stabilized disease ≥ (at or longer than) 16 weeks.

Dr. Spitz and his co-authors concluded, “Buparlisib was well tolerated, however efficacy was limited despite selection of PI3K pathway aberrations. Future studies may provide insight into buparlisib efficacy by refining the molecular selection of different tumor types.”

To read the full study: http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=27251&path[]=88220

Additional resource: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142564/

# # #

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report. 

Founded in 1984, FCS is one of the largest medical oncology/hematology practices in the United States. With more than 230 physicians, 220 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings, close to home.

Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy.  Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

*Prior to approval

For More Information, Contact:
Shelly Glenn, Chief Marketing & Sales Officer
SGlenn@FLCancer.com
(770) 365.6168

Michelle Robey, Director of Marketing & Communications
Michelle.Robey@FLCancer.com
(813) 767.9398